Denny Won

Cooley advised the underwriters of Aardvark Therapeutics, a phase 3 biotech company developing novel small-molecule therapies for metabolic diseases, in connection with Aardvark’s $94.2 million initial public offering (IPO).

Cooley advised SiteOne Therapeutics, a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough and other conditions, on its $100 million Series C financing.

Cooley advised the underwriters of Septerna, a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, on its upsized $331.2 million initial public offering.

Cooley advised the underwriters of Upstream Bio, a clinical-stage biotech developing a monoclonal antibody to target respiratory disorders, on its upsized $293 million initial public offering.

Cooley advised the underwriters of BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases, on its $198 million initial public offering.